The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Growth hormone and IGF-1
Does it raise growth hormone?
Raising growth hormone is easy to measure and easy to demonstrate. Whether raising it does anything you want is a separate question with much weaker evidence.
201,403 people · 37 human studies · 23 compounds
- 200,535 people5 studies
The epidemiology that any page about giving people more IGF-1 has to state. 199,698 men in UK Biobank followed a mean of 6.9 years, 5,402 diagnosed with and 295 dying from prostate cancer. Higher circulating IGF-1 was associated with prostate cancer diagnosis (hazard ratio 1.09 per 5 nmol/L increment, 95 percent CI...
International Journal of Cancer, 2021 · 199,698 people
Surveillance registry data from December 2008 to May 2021, 306 patients enrolled, 84.6 percent with severe primary IGF-1 deficiency. 80 patients had at least one hypoglycaemia adverse event against 224 with none. Total hypoglycaemia events were 0.11 per patient per treatment year and serious events 0.01 per patient...
Journal of Clinical Endocrinology and Metabolism, 2023 · 306 people
Ongoing open-label observational registry (NCT00903110), 242 children and adolescents from ten European countries enrolled between 2008 and 2017. In the treatment-naive prepubertal cohort of 138, height standard deviation score gain after one year was greater in the 21 patients with Laron syndrome than in the 117...
European Journal of Endocrinology, 2021 · 242 people
- 188 people2 studies1 found nothing
123 elderly hip-fracture patients: gait speed improved and IGF-1 rose, but most functional measures did not, and the trial was terminated early over a congestive heart failure safety signal.
Archives of Gerontology and Geriatrics, 2011 · 123 people
found nothing65 adults aged 60 to 81 on MK-677 25 mg daily for up to 2 years: GH and IGF-1 rose to young-adult levels and fat-free mass increased 1.1 kg vs a 0.5 kg loss on placebo, but strength and function did not improve and fasting glucose and insulin resistance rose.
Annals of Internal Medicine, 2008 · 65 people
- 152 people1 study
152 adults aged 55 to 87 (66 with MCI): 20 weeks of tesamorelin 1 mg daily had a favorable effect on cognition (P=.03), mainly executive function, and raised IGF-1 117% within the physiological range.
Archives of Neurology, 2012 · 152 people
- 152 people1 study
152 adults aged 55 to 87, of whom 66 had mild cognitive impairment. Twenty weeks of tesamorelin at 1 mg daily had a favourable effect on cognition, P equal to 0.03, concentrated in executive function, and raised IGF-1 by 117 percent within the physiological range. Note the dose: 1 mg, which is half the dose that...
Archives of Neurology, 2012 · 152 people
- 115 people1 study
115 patients: octreotide lowered GH to below 5 micrograms/L in 53% and normalized IGF-1 in 68%.
Annals of Internal Medicine, 1992 · 115 people
- 65 people1 study
65 healthy adults aged 60 to 81 took MK-677 25 mg orally once daily or placebo for two years in a double-blind randomised modified-crossover trial. Growth hormone and IGF-1 rose into the healthy young adult range without serious adverse events. Fat-free mass increased 1.1 kg on MK-677 against a 0.5 kg fall on placebo,...
Annals of Internal Medicine, 2008 · 65 people
- 63 people4 studies1 found nothing
found nothing26 normal subjects in three age bands from 19 to 96 given a combined intravenous bolus of 90 micrograms GHRH plus 90 micrograms GHRP-6. Mean growth hormone peaks were 47.5, 52.9 and 76.0 micrograms per litre with no significant differences between age groups, and there were no non-responders. Shows the combined...
Journal of Clinical Endocrinology and Metabolism, 1998 · 26 people
Twenty patients received GHRP-6 at 1 microgram per kilogram alone and, on a separate day, GHRP-6 with GHRH at 1 microgram per kilogram. In the growth hormone sufficient group the mean peak was 25.7 micrograms per litre alone and 54.7 combined; in the deficient group 1.3 versus 4.0. The combination is genuinely better...
European Journal of Endocrinology, 2002 · 20 people
In 10 healthy old men, 14 days of GHRH 1-29 at 1 mg twice daily restored 24-hour growth hormone and IGF-1 to levels not significantly different from young men. The best human result for the sermorelin half, and note the dose: 1,000 micrograms twice a day, several times what a blend draw delivers.
Journal of Clinical Endocrinology and Metabolism, 1992 · 10 people
- 60 people1 study
60 hypopituitary adults on GH for a mean of 10 years were crossed over to four months of placebo. IGF-1 fell from 168 to 98 micrograms per litre, two quality-of-life domains deteriorated, waist circumference and visceral fat rose, and lipids and C-reactive protein worsened, while insulin sensitivity improved.
Journal of Clinical Endocrinology and Metabolism, 2012 · 60 people
- 16 people1 study1 found nothing
found nothing16 healthy men, mean age 29, randomised to eight weeks of resistance training alone (n equals 7) or with ursolic acid (n equals 9), one capsule three times daily. Body fat percentage fell significantly in the supplemented group (p less than 0.001) while body weight, body mass index, lean body mass, glucose and insulin...
Korean Journal of Physiology and Pharmacology, 2014 · 16 people
- 13 people3 studies3 found nothing
found nothingSeven healthy male volunteers given an intravenous glucose tolerance test alone and with porcine galanin at 80 and 160 pmol/kg per minute. Galanin inhibits glucose-stimulated insulin release in dogs and rodents; in humans it had no effect on plasma glucose or serum insulin, though growth hormone still rose. The...
Diabetes, 1989 · 7 people
found nothingHuman galanin, not porcine, infused at 74 pmol/kg per minute for 60 minutes into six healthy volunteers during a hyperglycaemic clamp. Galanin concentrations plateaued around 1500 pmol/L against pre-infusion levels of 20 to 30 pmol/L. Growth hormone rose eightfold. Insulin, C-peptide, glucagon and glucose curves were...
Diabetologia, 1993 · 6 people
found nothingThe first human study. Galanin infused for 60 minutes into healthy volunteers at 7.8 pmol/kg per minute (n=4) or 33.2 pmol/kg per minute (n=6). Plasma growth hormone rose from 2.8 to a mean peak of 48.5 mU/L at the high dose and from 2.5 to 23.5 mU/L at the low dose; prolactin rose from 176 to 274 mU/L. No change in...
The Lancet, 1986 · no headcount in the line
- 12 people1 study
Twice-daily hexarelin for 16 weeks in 12 healthy elderly people cut the GH response by roughly half; attenuation was partial and reversed 4 weeks after stopping.
Growth Hormone and IGF Research, 1998 · 12 people
- 11 people2 studies1 found nothing
found nothingThe unmodified parent peptide in people. Eleven short children with normal growth hormone secretion were given GRF 1-29 amide at 5 micrograms per kilogram subcutaneously each evening for 6 months. Growth velocity increased in all of them, but the 24 hour growth hormone secretory profile did not differ before, during...
Hormone Research, 1988 · 11 people
Two randomised placebo-controlled double-blind ascending dose trials over 28 and 49 days in healthy subjects aged 21 to 61. A single injection raised mean plasma growth hormone 2 to 10 fold for 6 days or more and IGF-1 1.5 to 3 fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 still above...
Journal of Clinical Endocrinology and Metabolism, 2006 · no headcount in the line
- 11 people1 study
11 patients with prolactinomas (8 micro, 3 macro). No prolactin response to dermorphin in any patient; growth hormone rose in all except the 3 with macroprolactinomas. Used as an opioid probe of pituitary regulation, not as a treatment. Academic study, Italy.
Metabolism, 1985 · 11 people
- 10 people1 study
In 10 healthy old men, 14 days of GHRH(1-29) 1 mg twice daily restored 24-hour GH and IGF-1 to levels not significantly different from young men.
Journal of Clinical Endocrinology & Metabolism, 1992 · 10 people
- no headcount stated2 studies1 found nothing
Two randomized placebo-controlled trials in healthy adults: a single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days; estimated half-life 5.8 to 8.1 days.
Journal of Clinical Endocrinology & Metabolism, 2006 · no headcount in the line
found nothingIn healthy men, CJC-1295 raised trough GH 7.5-fold, mean GH 46% and IGF-1 45% one week after a single dose while GH pulse frequency and amplitude were unchanged.
Journal of Clinical Endocrinology & Metabolism, 2006 · no headcount in the line
- no headcount stated2 studies
GHRH 1-29, the molecule sold as sermorelin, was compared against growth hormone itself for stimulating growth in children with growth hormone deficiency. This is the kind of evidence that sat behind sermorelin's approval, and it is a paediatric deficiency population, not healthy adults seeking body composition change.
Acta Paediatrica Supplement, 1993 · no headcount in the line
In healthy older adults a ghrelin-receptor agonist combined with GHRH over 24 hours raised growth hormone secretion above either agent alone. It is the best evidence that the two-receptor idea works in people, and it used GHRP-2 with GHRH by infusion, not sermorelin with ipamorelin from a compounded vial.
Journal of Clinical Endocrinology and Metabolism, 2004 · no headcount in the line
- no headcount stated2 studies
Single subcutaneous injections in healthy adults raised mean plasma growth hormone two to ten-fold for six days or more and IGF-1 1.5 to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 above baseline for up to 28 days after multiple doses. A component lasting that long...
Journal of Clinical Endocrinology and Metabolism, 2006 · no headcount in the line
A 24 hour infusion combining a ghrelin-receptor agonist with GHRH raised growth hormone secretion above either agent given alone in healthy older adults. One GHRP was enough to show the two-receptor effect; nothing in this literature supports adding a second agent at the same receptor.
Journal of Clinical Endocrinology and Metabolism, 2004 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingSummary of six randomized, double-blind, placebo-controlled human trials: AOD9604 (Tyr-hGH177-191) had no effect on IGF-1 or glucose tolerance and a safety profile indistinguishable from placebo; the programme did not establish efficacy for weight loss.
Journal of Endocrinology and Metabolism, 2013 · no headcount in the line
- no headcount stated1 study
Randomised, up to 24 months of oxandrolone in severely burned children with five-year follow-up. Significant improvement in whole-body bone mineral content, lumbar spine bone mineral content and density, and height velocity, with treated children showing significantly greater height velocity throughout the first two...
Shock, 2016 · no headcount in the line
- no headcount stated1 study
Two randomised placebo-controlled trials in healthy adults. A single injection of CJC-1295 raised mean growth hormone 2-fold to 10-fold for six days or more and IGF-1 1.5-fold to 3-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days. This is the CJC-1295 component alone. No ipamorelin was...
Journal of Clinical Endocrinology and Metabolism, 2006 · no headcount in the line
- no headcount stated1 study
In healthy older adults, a 24 hour infusion of GHRP-2 combined with GHRH drove growth hormone secretion more than GHRH alone, and more than GHRP-2 alone. Acute two-peptide synergy was three-fold greater in young than older volunteers and 2.3-fold higher in elderly women than men. Thirty days of continuous GHRP-2...
Journal of Clinical Endocrinology and Metabolism, 2004 · no headcount in the line
- no headcount stated1 study
Single subcutaneous injections of CJC-1295 with drug affinity complex raised mean plasma growth hormone two to ten-fold for six days or more and IGF-1 1.5 to three-fold for nine to eleven days in healthy adults, with an estimated half-life of 5.8 to 8.1 days. The material usually sold as CJC-1295 without DAC is a...
Journal of Clinical Endocrinology and Metabolism, 2006 · no headcount in the line
- no headcount stated1 study
GHRH 1-29, the molecule sold as sermorelin, compared against growth hormone itself for stimulating growth in children with growth hormone deficiency. The kind of evidence behind sermorelin's former approval, in a paediatric deficiency population.
Acta Paediatrica Supplement, 1993 · no headcount in the line
- no headcount stated0 studies
A cautionary species difference: four days of LR3 IGF-I infusion in pigs decreased daily gain, food intake, plasma GH, IGFBP-3 and endogenous IGF-I.
Journal of Endocrinology, 1997 · no headcount in the line
Muscle-restricted IGF-1 expression in mice produced persistent hypertrophy and preserved regenerative capacity into old age, the mechanistic basis for IGF-1 muscle research.
Nature Genetics, 2001 · no headcount in the line
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.